GlassScriptPhysician profile
Tejas A Mehta
NPI 1952342438
$4,717.62
in general payments reported to CMS, 2019-2025
30 companies · $696 in 2025
The $696 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $1,393 · 2021: $219 · 2022: $632 · 2023: $616 · 2024: $851 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,164.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,376.84 | 2019-2023 | Impella |
| Abbott Laboratories | $587.56 | 2021-2024 | Portico, Esprit, Mitraclip |
| Novartis Pharmaceuticals Corporation | $373.68 | 2019-2025 | |
| Boston Scientific Corporation | $295.42 | 2022-2025 | Avvigo Guidance System, Cds - Mct/Cem Monitoring |
| Medtronic, INC. | $201.59 | 2022-2025 | Corevalve Evolut R, Symplicity G3 |
| Amgen INC. | $193.07 | 2020-2025 | Repatha |
| Shockwave Medical, INC | $178.58 | 2022 | |
| Zoll Circulation INC | $171.50 | 2022-2023 | Downstream Cartridge, Catheter, Therox Ds2 Console |
| Astrazeneca Pharmaceuticals LP | $156.93 | 2019-2025 | Farxiga, Brilinta |
| Cardiva Medical, INC. | $150.22 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Cardiovascular Systems INC. | $130.95 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.03 | 2023-2024 | Lifevest |
| Novo Nordisk INC | $108.46 | 2024-2025 | Wegovy, Ozempic |
| Pfizer INC. | $95.76 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.10 | 2019-2024 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $71.47 | 2022-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $70.71 | 2024-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $60.89 | 2022 | |
| Penumbra, INC. | $48.00 | 2019 | |
| Biosense Webster, INC. | $38.66 | 2020-2021 | |
| Esperion Therapeutics, INC. | $32.62 | 2025 | Nexletol |
| Biotronik INC. | $30.17 | 2019-2022 | |
| Edwards Lifesciences Corporation | $24.59 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Cordis US Corp. | $23.83 | 2025 | Mynxgrip |
| Bayer Healthcare Pharmaceuticals INC. | $22.15 | 2025 | |
| Covidien LP | $20.18 | 2020 | |
| Philips North America LLC | $19.99 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $19.65 | 2023 | Arcalyst |
| Terumo Medical Corporation | $13.31 | 2019 | |
| Cvrx, INC. | $9.71 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejas Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.